abbvie

Latest Posts

Biopharmaceutical firm AbbVie, Inc. (NYSE: ABBV) introduced first-quarter 2025 monetary outcomes, reporting a rise...

Market

AbbVie Q1 2025 adjusted earnings improve on 8% income development; beat estimates | AlphaStreet

Biopharmaceutical firm AbbVie, Inc. (NYSE: ABBV) introduced fourth-quarter 2024 monetary outcomes, reporting a double-digit...

Market

AbbVie This autumn 2024 adjusted earnings decline regardless of 6% income development | AlphaStreet

Specialty biopharmaceutical firm AbbVie, Inc. (NYSE: ABBV) Thursday introduced second-quarter 2024 monetary outcomes, reporting...

Market

AbbVie Q2 2024 adj. revenue drops regardless of greater revenues; outcomes beat | AlphaStreet